跳至主導覽
跳至搜尋
跳過主要內容
國立成功大學 首頁
English
中文
在 國立成功大學 搜尋內容
首頁
概要
研究單位
研究成果
專案
學生論文
設備
獎項
活動
查看斯高帕斯 (Scopus) 概要
李 明吉
Doctor
內科部
電子郵件
n510386
mail.hosp.ncku.edu
tw
h-index
932
引文
15
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
2011
2026
每年研究成果
概覽
指紋
網路
研究成果
(52)
類似的個人檔案
(6)
指紋
查看啟用 Ming-Chi Li 的研究主題。這些主題標籤來自此人的作品。共同形成了獨特的指紋。
排序方式
重量
按字母排序
Keyphrases
Bloodstream Infection
30%
Yeast Isolate
27%
Klebsiella Pneumoniae Carbapenemase
27%
Klebsiella Pneumoniae Bacteremia
27%
VITEK MS
21%
Minimum Inhibitory Concentration
18%
Uncommon Candida Species
17%
Cefepime
16%
Empirical Therapy
15%
Adjusted Odds Ratio
15%
Non-associated
15%
Combination Therapy
15%
Confidence Interval
14%
Aeromonas Veronii
13%
Pneumomediastinum
13%
Hospitalized Adults
13%
Pseudomonas Aeruginosa Bacteraemia
13%
Dengue Fever
13%
Occurrence Trends
13%
Time to Positivity
13%
Genotypic Characteristics
13%
Clinical Impact
13%
Rapid Species Identification
13%
Taiwan
13%
Species Identification
13%
Cerebral Aspergillosis
13%
Gram-negative Non-fermenters
13%
Immunocompromised Patients
13%
Species Susceptibility
13%
Organism Identification
13%
Carbapenems
13%
HIV-1 CRF01_AE
13%
Near Full-length Genome
13%
CRF01_AE
13%
Patient Diagnostics
13%
Community-onset
13%
Subspeciality
13%
Enterobacteriaceae Bacteraemia
13%
Clinical Standards
13%
Laboratory Standards
13%
Third-generation Cephalosporins
13%
Virulence Diversity
13%
Living with
13%
Algaemia
13%
Infected Individual
13%
Pneumocystis Jirovecii
13%
Antifungal Susceptibility
13%
Treatment Outcome
13%
Clinical Characteristics
13%
Diagnostic Challenge
13%
Medicine and Dentistry
Bloodstream Infection
55%
Infection
39%
Emergency Department
34%
Pathogen
29%
Mortality Rate
28%
Immunocompromised Patient
27%
Polymerase Chain Reaction
22%
Opportunistic Infection
22%
Klebsiella pneumoniae
18%
Enterobacteriaceae
16%
Human immunodeficiency virus
13%
Pneumomediastinum
13%
Clostridium Difficile Infection
13%
COVID-19
13%
Severe Acute Respiratory Syndrome Coronavirus 2
13%
Extended Spectrum Beta Lactamase
13%
Combination Therapy
13%
Aeromonas veronii
13%
Candidemia
13%
Dengue Fever
13%
Central Nervous System Aspergillosis
13%
Vibrio
13%
DNA Microarray
13%
Antibiogram
13%
Efavirenz
13%
Pontiac Fever
13%
Nursing Home
13%
Carbapenem
13%
Disease Course
13%
Antifungal Susceptibility
13%
Community-Acquired Pneumonia
12%
Matrix Assisted Laser Desorption Ionization Time of Flight Mass Spectrometry
11%
Diseases
10%
Health Care Facility
10%
Cohort Analysis
10%
Odds Ratio
9%
Malignant Neoplasm
9%
Escherichia coli
9%
Retrospective Study
9%
Charlson Comorbidity Index
9%
Hospital Mortality
7%
Quantitative Reverse Transcription Polymerase Chain Reaction
6%
Severe Acute Respiratory Syndrome
6%
Health Care Associated Pneumonia
6%
Healthcare Associated Infection
6%
Pyrrole Derivative
6%
Pyrrole
6%
Care Group
6%
Coughing
6%
Pediatric Pneumonia
6%
Pharmacology, Toxicology and Pharmaceutical Science
Bloodstream Infection
100%
Infection
33%
Carbapenem
32%
Klebsiella pneumoniae
32%
Antiinfective Agent
31%
Cefepime
29%
Salmonella
27%
Mortality Rate
23%
Infectious Agent
20%
Enterobacteriaceae
17%
Candidemia
16%
Combination Therapy
15%
Extended Spectrum Beta Lactamase
14%
Dengue
13%
Inflammation
13%
Central Nervous System Aspergillosis
13%
Enterobacter Cloacae
13%
Atherosclerosis
13%
Vibrio
13%
Candidiasis
13%
Efavirenz
13%
Bacterial Endocarditis
13%
Pseudomonas aeruginosa
13%
Candida Auris
13%
Depressive Disorder
13%
Legionnaire Disease
13%
Vasculitis
13%
Endocarditis
12%
Community Acquired Pneumonia
10%
Comorbidity
10%
Escherichia coli
9%
Retrospective Study
8%
Antimicrobial Therapy
8%
Health Care Associated Pneumonia
6%
Galactomannan
6%
Diseases
6%
Carbapenemase
5%
Minimum Inhibitory Concentration
5%
Hospital Mortality
5%
Antibiotic Therapy
5%
Fluconazole
5%
Matrix-Assisted Laser Desorption/Ionization
5%
Pyrrole
5%
Echinocandin
5%
Clinical Feature
5%
